EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy

Huqin Yang, Leyi Gao, Yi Xue, Zhijin Zhang, Lujia Guan, Haifan Zhang, Haomiao Ma, Xuyan Li, Jieqiong Li, Zhaohui Tong iD

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Huqin Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical Unive…. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported by the Ministry of Science and Technology of the People's Republic of China [2023YFC0872500], Beijing Research Center for Respiratory….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nirmatrelvir‐ritonavir (NMV‐r) has been widely used to treat coronavirus disease 2019 (COVID‐19) for a standard period of 5‐days. However, there are increasing reports of patients with persistent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) positivity after the standard 5‐day course of NMV‐r treatment. Moreover, the clinical characteristics of these patients and the efficacy of extending NMV‐r treatment duration are not fully understood. We conducted a prospective study involving hospitalized patients with COVID‐19. In total, 310 patients were included: 133 with SARS‐CoV‐2 RNA positivity after completion of the standard course of NMV‐r (positive group) and 177 without SARS‐CoV‐2 positivity (negative group). A subset of patients ( n = 37) in the positive group extended the treatment with NMV‐r. Patients in the positive group had higher severity scores, neutrophil counts, lactate dehydrogenase levels, and viral loads at admission. Following the standard 5‐day NMV‐r course, the positive group showed a significantly increased risk of composite disease progression outcomes (hazard ratio [HR] 3.35, 95% confidence interval [CI]: 2.07–5.44; p < 0.0001). This group also demonstrated higher risks of 28‐day all‐cause mortality, initiation of invasive mechanical ventilation, intensive care unit (ICU) admission and prolonged hospitalization. However, no significant differences in clinical outcomes were observed between the standard and the extended treatment groups in the unadjusted analysis. After adjustment for baseline characteristics, the extended treatment group demonstrated significantly better outcomes compared with the standard treatment group. Specifically, the extended treatment group had lower rates of composite disease progression (HR: 0.39, 95% CI: 0.20–0.79; p = 0.009), invasive mechanical ventilation (HR: 0.24, 95% CI: 0.08–0.73; p = 0.01), and ICU admission (HR: 0.15, 95% CI: 0.02–0.94; p = 0.04), along with a shorter length of hospital stay (HR: −13.54, 95% CI: −26.01 to −1.07; p = 0.033). SARS‐CoV‐2 positivity after NMV‐r treatment is common and associated with worse clinical outcomes. Extending NMV‐r therapy may reduce disease progression risk; this finding requires confirmation in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirCOVID-19 Drug TreatmentAntiviral AgentsHumansMaleFemaleMiddle AgedProspective StudiesTreatment OutcomeAgedSARS-CoV-2Viral LoadCOVID-19Disease ProgressionAdultHospitalizationSeverity of Illness Index

Stichwörter der Autor:innen

COVID‐19extended treatmentnirmatrelvir‐ritonavirpersistent infection

Substanzen

RitonavirAntiviral Agents

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
  • Beijing Research Center for Respiratory Infectious Diseases, Beijing, China.
  • Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Zhaohui Tong

Förderung

  • This study was supported by the Ministry of Science and Technology of the People's Republic of China [2023YFC0872500], Beijing Research Center for Respiratory…

Zitieren

APA

Yang, H., Gao, L., Xue, Y., Zhang, Z., Guan, L., Zhang, H., Ma, H., Li, X., Li, J., & Tong, Z. (2025). Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy. Journal of Medical Virology. https://doi.org/10.1002/jmv.70377

Vancouver

Yang H, Gao L, Xue Y, Zhang Z, Guan L, Zhang H, et al. Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy. Journal of Medical Virology. 2025. doi:10.1002/jmv.70377

BibTeX
@article{Yang2025,
  author = {Yang, Huqin and Gao, Leyi and Xue, Yi and Zhang, Zhijin and Guan, Lujia and Zhang, Haifan and Ma, Haomiao and Li, Xuyan and Li, Jieqiong and Tong, Zhaohui},
  title = {Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70377}
}
Kostenlos starten →